Simvastatin Reduces Circulating Plasminogen Activator Inhibitor 1 Activity in Volunteers with the Metabolic Syndrome

Abstract

Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity.